Noom peptides are now available through OpenRx, its new preventive health brand. The launch has four prescription options: two injections and two dissolving tablets. BPC-157 and TB-500 are still being evaluated, rather than listed as launch treatments.

As of November 19, 2026, the day this article was written, Noom's November 17 announcement describes a new service, not new trial results. A familiar company name tells someone where care is offered. It doesn't settle whether a particular treatment fits their health or goals.

Noom peptides: what OpenRx launched

Peptides are short chains of protein building blocks. OpenRx groups them with other medicines, so its menu isn't entirely peptides.

OpenRx launch option What it contains
Sermorelin injection A peptide that copies the body's growth-hormone release signal
NAD+ injection A coenzyme, a helper molecule cells use in making energy
PT-141, oxytocin and tadalafil dissolving tablet Three medicines combined in one sexual health preparation
Oxytocin dissolving tablet A hormone, or chemical messenger, marketed for intimacy

These are the options Noom announced, not four treatments with the same evidence. NAD+ and tadalafil aren't peptides. PT-141 is also called bremelanotide, a peptide studied for distressing low sexual desire.

Noom's chief medical officer, Jeffrey Egler, said: “We are currently reviewing BPC-157 and TB-500”. Reviewing means considering them; it doesn't announce a prescription launch or a start date.

Sermorelin signals the pituitary, a small gland beneath the brain, to release growth hormone. It doesn't supply growth hormone itself. Our sermorelin explainer separates that mechanism from the adult goals people hear about online.

Who prescribes, and what compounded means

Noom says: “Every OpenRx prescription is written by a licensed clinician”. The release describes an evaluation of health history, goals and clinical fit. It says prescriptions are fulfilled through a network of U.S. compounding pharmacies, with state pharmacy-board oversight.

Compounding means preparing a medicine for a particular prescription. On OpenRx's own website, the disclosure reads: “Compounded medications have not been reviewed or approved by the FDA for safety, efficacy, or quality.” Efficacy means whether a treatment works.

The ingredient's history and the finished preparation's status need to stay separate:

  • Sermorelin: Compounded sermorelin is different from the FDA-approved product once sold as Geref, which has since been discontinued. FDA's 2013 determination found the withdrawal was not for safety or effectiveness reasons. Today's compounded formulation is not FDA-approved.
  • PT-141: A compounded combination tablet is different from FDA-approved Vyleesi, a bremelanotide injection. The tablet itself is not FDA-approved; Vyleesi's review doesn't cover a new mixture or delivery method.
  • Oxytocin and tadalafil: Both have approved products for other medical uses. Those include oxytocin injections for childbirth care and tadalafil tablets for erection problems and urinary symptoms from an enlarged prostate. Neither approval transfers to either OpenRx compounded tablet.
  • NAD+: It has no FDA-approved drug form. As of November 19, 2026, the day this article was written, the FDA's drug records, updated that day, list no NAD+ drug product.

A licensed provider may still prescribe — that decision is between you and your doctor.

What the launch tells us about muscle and energy

A new service can change access without changing the evidence behind the medicine. That matters when a treatment is presented around a broad goal such as better recovery or more energy.

For sermorelin, human studies exist, but each answers a specific question. A 2006 trial by Vitiello and colleagues in Neurobiology of Aging assigned 100 healthy older adults to sermorelin or placebo, an inactive comparison treatment. Eighty-nine completed six months. Researchers reported improvements on selected thinking tests; that finding doesn't establish broad muscle, recovery or longevity benefits.

For NAD+, its role inside cells doesn't establish that an injection improves someone's daily energy. Research on supplements the body converts into NAD+ also doesn't establish the effects of injected NAD+. The NAD+ injection guide explains those separate evidence questions.

A three-drug tablet needs its own evidence

Combining three ingredients creates a formulation with its own unanswered questions. No published human trial has established how this three-drug tablet performs. OpenRx's evidence notes describe studies of individual ingredients and say those studies did not test its combination.

The RECONNECT trials, published in Obstetrics & Gynecology in 2019, included 1,267 women before menopause, when menstrual periods end. All had distressing low sexual desire. They were assigned by chance to bremelanotide injections or placebo for 24 weeks. Desire and related distress scores improved, while nausea, flushing and headache were more common with treatment.

Those trials did not test a dissolving tablet, the three-drug combination or men. Our PT-141 explainer covers that evidence separately.

As of November 19, 2026, the day this article was written, a November 6 review in The Journal of Sexual Medicine draws together earlier studies of peptides in men. It describes small studies, short follow-up and few direct comparisons. The current FDA Vyleesi label carries “Revised: 10/2026”.

The label covers a specific low-desire disorder in women before menopause. It does not indicate the injection for men or sexual-performance enhancement. It lists uncontrolled high blood pressure or known heart or blood-vessel disease as contraindications, meaning reasons not to use it.

The combination has its own safety information, too. OpenRx says the tablet must never be taken with nitrates, medicines that include nitroglycerin for chest pain. It must never be taken with riociguat, a medicine for certain lung blood-pressure conditions, either. With tadalafil, OpenRx says, those medicines can cause a severe, potentially fatal drop in blood pressure. It also says not to use the tablet with uncontrolled high blood pressure or known heart disease. Its page says to get medical help right away for an erection lasting more than 4 hours or sudden loss of vision or hearing.

What to watch next

As of November 19, 2026, the day this article was written, Hims & Hers also launched Peptides+ on November 18, with a separate Hers announcement that day. The Hims peptides guide follows that company's separate rollout.

HHS, the Department of Health and Human Services, called its peptide compounding policy a draft in its October 30 notice. The HHS policy explainer covers its conditions; the document doesn't add clinical trial results.

For OpenRx, the next concrete developments would be a named addition to the menu or published evidence for a specific formulation. Noom's review of BPC-157 and TB-500 leaves both questions open.

For future studies, the useful question is what outcome was measured in people receiving the same medicine by the same route. A higher blood marker and feeling better are different outcomes.

At Promise, a licensed provider reviews every request, and not everyone qualifies. Sermorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.